NDA 212904 · Aveo Pharms
Fotivda
Tivozanib Hydrochloride · Oral
NovelCDER novel approval, Mar 10, 2021: To treat renal cell carcinoma
Last checked: Nov 19, 2026Latest source record: Jan 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Mar 10, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
40
5 Phase 3, 4 recruiting
FAERS reports
1,610
603 serious, 159 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 11, 2026.
FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. ( 1 )
Mechanism: Tivozanib is a tyrosine kinase inhibitor. In vitro cellular kinase assays demonstrated that tivozanib inhibits phosphorylation of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3 and inhibits other kinases including c-kit and PDGFR β at clinically relevant concentrations. In tumor xenograft models in mice and rats, tivozanib inhibited angiogenesis, vascular permeability, and tumor growth of various tumor cell types including human renal cell carcinoma.
Therapeutic areas: Oncology · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- FOTIVDA · TIVOZANIB HYDROCHLORIDE EQ 1.34MG BASE · CAPSULE, ORAL · Prescription
- FOTIVDA · TIVOZANIB HYDROCHLORIDE EQ 0.89MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tivozanib" as an intervention, any sponsor and status, largest first.
- Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerPivotal-lookingRecruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT06661720 · 1,040 participants (planned) · Start Mar 14, 2025 · Primary completion Nov 2037
Drug: Pembrolizumab; Tivozanib · For: Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma (RCC); Stage II Renal Pelvis Cancer AJCC v8 and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Jonesboro, Arkansas · 429 sites in all
- A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell CarcinomaPivotal-lookingCompleted
AVEO Pharmaceuticals, Inc.Industry
NCT01030783 · 517 participants · Start Dec 2009 · Primary completion Jul 2012
Drug: tivozanib (AV-951); Sorafenib · For: Advanced Renal Cell Carcinoma
Sites: Los Angeles, California; Gainesville, Florida; Orlando, Florida · 86 sites in all
Arcus Biosciences, Inc.Industry
NCT05536141 · 512 participants (planned) · Start Oct 26, 2022 · Primary completion Mar 2029
Drug: Casdatifan; Cabozantinib and 5 more · For: Clear Cell Renal Cell Carcinoma; Solid Tumors
Sites: Birmingham, Alabama; San Diego, California; Santa Monica, California · 25 sites in all
- A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)Pivotal-lookingCompleted
AVEO Pharmaceuticals, Inc.Industry
NCT02627963 · 350 participants · Start May 24, 2016 · Primary completion Oct 4, 2018
Drug: Tivozanib hydrochloride; Sorafenib · For: Carcinoma, Renal Cell
Sites: Phoenix, Arizona; Scottsdale, Arizona; Duarte, California · 191 sites in all
- Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaPivotal-lookingCompleted
AVEO Pharmaceuticals, Inc.Industry
NCT04987203 · 343 participants · Start Sep 9, 2021 · Primary completion Jan 20, 2026
Drug: Tivozanib; Nivolumab · For: Renal Cell Carcinoma
Sites: Duarte, California; Irvine, California; La Jolla, California · 139 sites in all
- An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).Pivotal-lookingCompleted
AVEO Pharmaceuticals, Inc.Industry
NCT01076010 · 277 participants · Start Mar 2010 · Primary completion Jul 2014
Drug: Tivozanib; Sorafenib · For: Advanced Renal Cell Carcinoma
Sites: Los Angeles, California; Orlando, Florida; Minneapolis, Minnesota · 75 sites in all
- A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell CarcinomaPivotal-lookingCompleted
AVEO Pharmaceuticals, Inc.Industry
NCT00502307 · 272 participants · Start Oct 2007 · Primary completion Aug 2010
Drug: Tivozanib (AV-951); Placebo comparator · For: Carcinoma, Renal Cell
Sites: Vellore, India; Kolkata, India; Mumbai, India · 26 sites in all
- A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line TherapyPivotal-lookingCompleted
AVEO Pharmaceuticals, Inc.Industry
NCT01478594 · 265 participants · Start Dec 2011 · Primary completion Sep 2013
Drug: Tivozanib; Bevacizumab and 1 more · For: Colorectal Cancer
Sites: Gilbert, Arizona; Hot Springs, Arizona; Tucson, Arizona · 73 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue316
- diarrhoea196
- blood pressure increased150
- nausea142
- disease progression139
- decreased appetite135
- dysphonia112
- death106
- asthenia93
- off label use93
- hypertension83
- vomiting73
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 6 |
| 2012 | 2 |
| 2013 | 14 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 9 |
| 2020 | 5 |
| 2021 | 349 |
| 2022 | 581 |
| 2023 | 230 |
| 2024 | 75 |
| 2025 | 209 |
| 2026 | 120 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fotivda (Tivozanib HCl)
2024 spending
$119M
Beneficiaries
993
4,132 claims
Per beneficiary
$119,739
$1,391.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $22,459,910 |
| 2022 | $72,738,998 |
| 2023 | $102,301,659 |
| 2024 | $118,900,829 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
Choueiri TK, Albiges L, Barthélémy P, et al. · Lancet 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Rini BI, Pal SK, Escudier BJ, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Comparative Study
- Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study.
Zugman M, McDermott DF, Escudier BJ, et al. · Oncologist 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
Molina AM, Hutson TE, Nosov D, et al. · Eur J Cancer 2018 · Clinical Trial, Phase III, Multicenter Study
- Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.
Caquelin L, Gewily M, Mottais W, et al. · BMC Cancer 2022 · Systematic Review
- Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
Kalpathy-Cramer J, Chandra V, Da X, et al. · J Neurooncol 2017 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
Sponsor: Aveo Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.